Biomarkers of neurodegeneration and glial activation validated in Alzheimer's disease assessed in longitudinal cerebrospinal fluid samples of Parkinson's disease.

<h4>Aim</h4>Several pathophysiological processes are involved in Parkinson's disease (PD) and could inform in vivo biomarkers. We assessed an established biomarker panel, validated in Alzheimer's Disease, in a PD cohort.<h4>Methods</h4>Longitudinal cerebrospinal flu...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Michael Bartl, Mohammed Dakna, Douglas Galasko, Samantha J Hutten, Tatiana Foroud, Marian Quan, Kenneth Marek, Andrew Siderowf, Jonas Franz, Claudia Trenkwalder, Brit Mollenhauer, Parkinson’s Progression Markers Initiative
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/2dd6276ca17c4e6e850a0ed593e32cff
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2dd6276ca17c4e6e850a0ed593e32cff
record_format	dspace
spelling	oai:doaj.org-article:2dd6276ca17c4e6e850a0ed593e32cff2021-12-02T20:17:14ZBiomarkers of neurodegeneration and glial activation validated in Alzheimer's disease assessed in longitudinal cerebrospinal fluid samples of Parkinson's disease.1932-620310.1371/journal.pone.0257372https://doaj.org/article/2dd6276ca17c4e6e850a0ed593e32cff2021-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0257372https://doaj.org/toc/1932-6203<h4>Aim</h4>Several pathophysiological processes are involved in Parkinson's disease (PD) and could inform in vivo biomarkers. We assessed an established biomarker panel, validated in Alzheimer's Disease, in a PD cohort.<h4>Methods</h4>Longitudinal cerebrospinal fluid (CSF) samples from PPMI (252 PD, 115 healthy controls, HC) were analyzed at six timepoints (baseline, 6, 12, 24, 36, and 48 months follow-up) using Elecsys® electrochemiluminescence immunoassays to quantify neurofilament light chain (NfL), soluble TREM2 receptor (sTREM2), chitinase-3-like protein 1 (YKL40), glial fibrillary acidic protein (GFAP), interleukin-6 (IL-6), S100, and total α-synuclein (αSyn).<h4>Results</h4>αSyn was significantly lower in PD (mean 103 pg/ml vs. HC: 127 pg/ml, p<0.01; area under the curve [AUC]: 0.64), while all other biomarkers were not significantly different (AUC NfL: 0.49, sTREM2: 0.54, YKL40: 0.57, GFAP: 0.55, IL-6: 0.53, S100: 0.54, p>0.05) and none showed a significant difference longitudinally. We found significantly higher levels of all these markers between PD patients who developed cognitive decline during follow-up, except for αSyn and IL-6.<h4>Conclusion</h4>Except for αSyn, the additional biomarkers did not differentiate PD and HC, and none showed longitudinal differences, but most markers predict cognitive decline in PD during follow-up.Michael BartlMohammed DaknaDouglas GalaskoSamantha J HuttenTatiana ForoudMarian QuanKenneth MarekAndrew SiderowfJonas FranzClaudia TrenkwalderBrit MollenhauerParkinson’s Progression Markers InitiativePublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 10, p e0257372 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Michael Bartl Mohammed Dakna Douglas Galasko Samantha J Hutten Tatiana Foroud Marian Quan Kenneth Marek Andrew Siderowf Jonas Franz Claudia Trenkwalder Brit Mollenhauer Parkinson’s Progression Markers Initiative Biomarkers of neurodegeneration and glial activation validated in Alzheimer's disease assessed in longitudinal cerebrospinal fluid samples of Parkinson's disease.
description	<h4>Aim</h4>Several pathophysiological processes are involved in Parkinson's disease (PD) and could inform in vivo biomarkers. We assessed an established biomarker panel, validated in Alzheimer's Disease, in a PD cohort.<h4>Methods</h4>Longitudinal cerebrospinal fluid (CSF) samples from PPMI (252 PD, 115 healthy controls, HC) were analyzed at six timepoints (baseline, 6, 12, 24, 36, and 48 months follow-up) using Elecsys® electrochemiluminescence immunoassays to quantify neurofilament light chain (NfL), soluble TREM2 receptor (sTREM2), chitinase-3-like protein 1 (YKL40), glial fibrillary acidic protein (GFAP), interleukin-6 (IL-6), S100, and total α-synuclein (αSyn).<h4>Results</h4>αSyn was significantly lower in PD (mean 103 pg/ml vs. HC: 127 pg/ml, p<0.01; area under the curve [AUC]: 0.64), while all other biomarkers were not significantly different (AUC NfL: 0.49, sTREM2: 0.54, YKL40: 0.57, GFAP: 0.55, IL-6: 0.53, S100: 0.54, p>0.05) and none showed a significant difference longitudinally. We found significantly higher levels of all these markers between PD patients who developed cognitive decline during follow-up, except for αSyn and IL-6.<h4>Conclusion</h4>Except for αSyn, the additional biomarkers did not differentiate PD and HC, and none showed longitudinal differences, but most markers predict cognitive decline in PD during follow-up.
format	article
author	Michael Bartl Mohammed Dakna Douglas Galasko Samantha J Hutten Tatiana Foroud Marian Quan Kenneth Marek Andrew Siderowf Jonas Franz Claudia Trenkwalder Brit Mollenhauer Parkinson’s Progression Markers Initiative
author_facet	Michael Bartl Mohammed Dakna Douglas Galasko Samantha J Hutten Tatiana Foroud Marian Quan Kenneth Marek Andrew Siderowf Jonas Franz Claudia Trenkwalder Brit Mollenhauer Parkinson’s Progression Markers Initiative
author_sort	Michael Bartl
title	Biomarkers of neurodegeneration and glial activation validated in Alzheimer's disease assessed in longitudinal cerebrospinal fluid samples of Parkinson's disease.
title_short	Biomarkers of neurodegeneration and glial activation validated in Alzheimer's disease assessed in longitudinal cerebrospinal fluid samples of Parkinson's disease.
title_full	Biomarkers of neurodegeneration and glial activation validated in Alzheimer's disease assessed in longitudinal cerebrospinal fluid samples of Parkinson's disease.
title_fullStr	Biomarkers of neurodegeneration and glial activation validated in Alzheimer's disease assessed in longitudinal cerebrospinal fluid samples of Parkinson's disease.
title_full_unstemmed	Biomarkers of neurodegeneration and glial activation validated in Alzheimer's disease assessed in longitudinal cerebrospinal fluid samples of Parkinson's disease.
title_sort	biomarkers of neurodegeneration and glial activation validated in alzheimer's disease assessed in longitudinal cerebrospinal fluid samples of parkinson's disease.
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/2dd6276ca17c4e6e850a0ed593e32cff
work_keys_str_mv	AT michaelbartl biomarkersofneurodegenerationandglialactivationvalidatedinalzheimersdiseaseassessedinlongitudinalcerebrospinalfluidsamplesofparkinsonsdisease AT mohammeddakna biomarkersofneurodegenerationandglialactivationvalidatedinalzheimersdiseaseassessedinlongitudinalcerebrospinalfluidsamplesofparkinsonsdisease AT douglasgalasko biomarkersofneurodegenerationandglialactivationvalidatedinalzheimersdiseaseassessedinlongitudinalcerebrospinalfluidsamplesofparkinsonsdisease AT samanthajhutten biomarkersofneurodegenerationandglialactivationvalidatedinalzheimersdiseaseassessedinlongitudinalcerebrospinalfluidsamplesofparkinsonsdisease AT tatianaforoud biomarkersofneurodegenerationandglialactivationvalidatedinalzheimersdiseaseassessedinlongitudinalcerebrospinalfluidsamplesofparkinsonsdisease AT marianquan biomarkersofneurodegenerationandglialactivationvalidatedinalzheimersdiseaseassessedinlongitudinalcerebrospinalfluidsamplesofparkinsonsdisease AT kennethmarek biomarkersofneurodegenerationandglialactivationvalidatedinalzheimersdiseaseassessedinlongitudinalcerebrospinalfluidsamplesofparkinsonsdisease AT andrewsiderowf biomarkersofneurodegenerationandglialactivationvalidatedinalzheimersdiseaseassessedinlongitudinalcerebrospinalfluidsamplesofparkinsonsdisease AT jonasfranz biomarkersofneurodegenerationandglialactivationvalidatedinalzheimersdiseaseassessedinlongitudinalcerebrospinalfluidsamplesofparkinsonsdisease AT claudiatrenkwalder biomarkersofneurodegenerationandglialactivationvalidatedinalzheimersdiseaseassessedinlongitudinalcerebrospinalfluidsamplesofparkinsonsdisease AT britmollenhauer biomarkersofneurodegenerationandglialactivationvalidatedinalzheimersdiseaseassessedinlongitudinalcerebrospinalfluidsamplesofparkinsonsdisease AT parkinsonsprogressionmarkersinitiative biomarkersofneurodegenerationandglialactivationvalidatedinalzheimersdiseaseassessedinlongitudinalcerebrospinalfluidsamplesofparkinsonsdisease
_version_	1718374396195766272

Biomarkers of neurodegeneration and glial activation validated in Alzheimer's disease assessed in longitudinal cerebrospinal fluid samples of Parkinson's disease.

Ejemplares similares